Market: Copenhagen
Symbol: VIRO
ISIN: DK0061030574
Industry: Health Care

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The products are primarily used at emergency departments in hospitals for risk stratification of acute medical patients to improve clinical decisions on discharge and hospitalization.

ViroGates’ suPARnostic® product range measures the protein, suPAR (soluble urokinase Plasminogen Activator Receptor). The protein is naturally occurring in human blood and reflects the immune system’s activation level. A patient’s suPAR level predicts negative outcomes such as short-term mortality across acute and chronic diseases. The suPARnostic® tests are easily integrated into existing hospital workflows and instruments, and the results are available in 10-20 minutes.

The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV infections and subsequently in many other disease areas. Headquartered in Birkerød, Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.

Share Data 27/01/2023
Previous Close 50.00
Change (%) 5.26
Volume 863
Number of Shares 3,350,507
Market Cap 167.53

KEY FIGURES - DKK('000) 2021 2020
Income statement    
Net revenue 7,656 5,354
Operating profit/loss -18,790 -19,729
Profit/loss for the year -17,663 -18,736
Balance sheet    
Balance sheet total 20,229 38,246
Equity 16,426 31,314
Invested capital 4,815 895
Cash flows    
Cash flows from operating activities -21,437 -15,602
Cash flows from investment related activities -4 -114
Cash flows from financing activities 2,776 7,835
Total cash flows -18,665 -7,881
Cash and cash equivalents 14,859 33,526
Rate of return -658.2 -1,028.1
Number of employees, end of period 13 14
Market share price, end of period (DKK) 144.0 81.5


At the end of 2021, ViroGates had 1,621 registered shareholders. Three shareholders had notified shareholdings of 5% or more:

Shareholders (31/12/2021) Number of shares Percent of capital
N. P. Louis-Hansen ApS 817,075 25.77%
Ginnerup Capital ApS 325,965 10.28%
4AM ApS 325,965 10.28%
* Other includes analysis services, freight and handling

Download PDF